



Letter to the Editor

Is CGRP Receptor Blockade Cardiovascularly Safe? Appropriate Studies are Needed

With great interest, we read the publication by Depre and colleagues¹ describing that inhibition of the canonical CGRP receptor does not seem to worsen myocardial ischemia contrary to theoretical concerns.² In a randomized, double-blind, placebo-controlled study the authors did not find evidence for an adverse effect of the CGRP receptor antibody erenumab on exercise time during a treadmill test in patients with stable angina. Although we certainly appreciate the endeavor to address this important issue, we are concerned that the study population, the study design, and the interpretation of the results do not allow for such a reassuring conclusion.

While the authors rightly indicate that it is currently not clear to which extent CGRP is relevant in maintaining blood flow in case of myocardial and cerebral ischemia, we do not agree with their argument stating that “the concentrations of exogenous CGRP required to increase total exercise time or protect against myocardial ischemia far exceed the endogenous physiological levels of CGRP that are released during a response to ischemia.” This is because it is not the *systemic plasma* concentration that is relevant in this perspective, but the actual concentration of CGRP *at the neuro-vascular junction*, where CGRP is released. Obviously, the plasma concentration is likely to be several log units lower than the junctional concentration due to dilution and hydrolysis. Further, we feel that the argument that erenumab does not contract the human isolated coronary artery per se³ does not add to the introduction, since the question that should be answered here is whether inhibition of the actions of CGRP is potentially harmful in myocardial ischemia.

More importantly, the patients included in this study suffered from stable angina pectoris, which often is caused by a stenosis of the epicardial conducting portions of the coronary artery. As we pointed out earlier,² the importance of CGRP in the proximal, epicardial portions of the coronary artery bed seems limited, while CGRP is a highly effective vasodilator in the intramyocardial, smaller (distal) sections of the coronary artery bed. Thus, it is unfortunate that a patient population with, most likely, mainly diseased proximal coronary arteries, was chosen for this study, despite the advantage of a clear-cut definition of these patients. Although stable angina pectoris due to epicardial stenosis may occur in both men and women, this is typically considered a “male” form of cardiac pathology,⁴ as illustrated by the fact that 78% of patients included in the current study were male. In contrast, in females, who are the majority of migraine sufferers and thus also the majority of the population likely to use erenumab or related drugs in future, coronary artery disease often presents as diffuse atherosclerosis, without an angiographically detectable stenosis.^{4–6} These observations indicate that coronary microvascular dysfunction plays a more important role in angina pectoris in female patients and that blocking the effects of CGRP in female patients may have different effects than in male patients.

An essential concern of this study is based on pharmacokinetic and pharmacodynamic considerations. The authors rightly indicate that plasma concentrations obtained 30 min after intravenous infusion of 140 mg erenumab (the time interval until the start of the

Conflict of Interest: AMvdB received research grants and/or consultation fees from Amgen/Novartis, Lilly/CoLucid, Teva, and ATI.

CMV received consultation fees from Lilly/CoLucid.

treadmill test) will provide “a substantial margin over concentrations achieved by subcutaneous administration of 140 mg.” In contrast, their claim that “the use of 140 mg intravenous dose of erenumab ensured rapid and robust blockade of the CGRP receptor” is not substantiated by any evidence. It should be taken into account that, before a receptor blocking antibody can effectively occupy the receptor where it is binding to, the antibody should first have access to the receptor biophase. In this case, erenumab was infused intravenously and thus reached the blood vessel wall from the luminal side. The CGRP receptor is located in the smooth muscle wall,⁵ thus it may take several hours before the receptor was reached by erenumab at sufficiently high concentrations to induce an effective blockade of the CGRP receptor, especially given the large molecular size (150 kDa) of erenumab. This is well beyond the time the treadmill test had finished. A way to verify whether blockade has been achieved (at least in skin blood vessels) is by assessing blockade of capsaicin-induced increases in dermal blood flow. The earliest time point for such measurements that has been published, to the best of our knowledge, for erenumab is 2 days after intravenous administration,⁶ which is about 100-fold longer than the period applied in the current study. Thus, we feel that evidence for significant blockade of the canonical CGRP receptor should have been provided to substantiate the statement that CGRP receptor blockade was reached *during* the treadmill study, since otherwise the interpretation of the current study is questionable.

Taken together, we would politely urge the authors to provide evidence for the fact that vascular CGRP receptor blockade has been achieved 30 min after intravenous infusion of erenumab, since this is a crucial part of the study. Further, we plead for cardiovascular safety studies on patients and/or experimental animals with microvascular disease, as such a group may better represent the patients at cardiovascular risk after the use of erenumab. Even if the

antibodies against CGRP or its receptor would not increase the risk for cardiovascular ischemia, there will be cases of patients with ischemic complaints, even without a causal relationship. Appropriate studies in relevant subjects may avoid sudden distress, such as happened with the triptans in the past.

A. Maassen van den Brink, PhD; E. Rubio-Beltrán, MSc; D. Duncker, MD, PhD; C.M. Villalón, PhD
Division of Pharmacology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands (A. Maassen van den Brink and E. Rubio-Beltrán); Department of Experimental Cardiology, Erasmus MC, Rotterdam, The Netherlands (D. Duncker); Department Pharmacobiology, Cinvestav-Coapa, Tlalpan, Mexico City, Mexico (C. Villalón)
e-mail: a.vanharen-maassenvandenbrink@erasmusmc.nl

REFERENCES

1. Depre C, Antalík L, Starling A, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. *Headache*. 2018;58:715-723.
2. MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD. Wiping out CGRP: Potential cardiovascular risks. *Trends Pharmacol Sci*. 2016;37:779-788.
3. Rubio-Beltrán E, Labastida A, De Vries R, et al. Effects of AMG 334 on human isolated coronary artery. *Cephalalgia*. 2016;36:S41.
4. Humphries KH, Pu A, Gao M, Carere RG, Pilote L. Angina with “normal” coronary arteries: Sex differences in outcomes. *Am Heart J*. 2008;155:375-381.
5. Maas AH, van der Schouw YT, Regitz-Zagrosek V, et al. Red alert for women’s heart: The urgent need for more research and knowledge on cardiovascular disease in women: Proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. *Eur Heart J*. 2011;32:1362-1368.
6. Duncker DJ, Koller A, Merkus D, Canty JM Jr. Regulation of coronary blood flow in health and ischemic heart disease. *Prog Cardiovasc Dis*. 2015;2015:409-422.
7. Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. *J Pharmacol Exp Ther*. 2010;334:746-752.
8. Vu T, Ma P, Chen JS, et al. Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects. *Pharm Res*. 2017;34:1784-1795.

Editorial Board

Editor-in-Chief
Thomas N. Ward, MD Hanover, NH

Senior Editorial Advisors
Robert B. Daroff, MD Cleveland, OH, USA
Anne Ducros Montpellier, France
Michel Ferrari, MD Leiden, The Netherlands
Peter J. Goadsby, MD, PhD, DSc London, United Kingdom
Donald Penzien, PhD Winston-Salem, North Carolina
John Rothrock, MD Washington, DC, USA

Associate Editors
Steven M. Baskin, PhD Stamford, CT, USA
Rebecca Burch, MD Boston, MA, USA
Gregory Dussor, PhD Dallas, Texas, USA
Deborah Friedman, MD Dallas, TX, USA
Amy Gelfand, MD, San Francisco, California, USA
Christopher Gottschalk, MD New Haven, CT, USA
Laine Greene Halifax, Nova Scotia, Canada
Lyn Griffiths, PhD Gold Coast, Australia
Andrew Hershey, MD, PhD, Cincinnati, OH, USA
Robert Kaniecki, MD Pittsburgh, PA, USA
Abouch Krymchantowski, MD, PhD Rio de Janeiro, Brazil
Morris Levin, MD San Francisco, CA
Dan Levy Boston, MA, USA
Elizabeth Loder, MD Boston, MA, USA
Vincent Martin, MD Cincinnati, OH, USA
Brian E. McGeeney, MD Boston, MA, USA
Mia Minen, MD New York, NY
Julio Pascual, MD, PhD Oviedo, Spain
B. Lee Peterlin, DO Baltimore, MD, USA
Luiz P. Queiroz, MD Florianopolis, Brazil
Paul B. Rizzoli, MD Boston, MA, USA
Matthew S. Robbins, MD Bronx, NY
Noah Rosen, MD Great Neck, New York, USA
Todd J. Schwedt, MD Phoenix, AZ, USA
Jonathan Smith, MD Lexington, KY, USA
Todd A. Smitherman, PhD Oxford, MS, USA
Till Sprenger, MD Basel, Switzerland
Jerry W. Swanson, MD, MHPE Rochester, MN, USA
Deborah E. Tepper, MD Sandwich, MA, USA
Stewart J. Tepper, MD Lebanon, NH, USA
Gretchen E. Tietjen, MD Toledo, OH, USA
Marcelo M. Valença, MD, PhD Recife, Brazil
Shuu-Jiun Wang, MD Taipei, Taiwan
Randall E. Weeks, PhD Stamford, CT, USA

Assistant Editors
Jennifer Hranilovich, MD Boston, MA, USA
Saad Kanaan, MD Boston, MA, USA
Amanda Maccone, MD Lebanon, NH, USA

Headache Currents Editor-in-Chief
Stewart J. Tepper, MD Lebanon, NH, USA

Online Editor
Todd Schwedt, MD Phoenix, AZ, USA

Associate Provider Editor
Lynda J Krasenbaum MSN, ANP-BC
New York, NY, USA

Supplement Editors
R. Allan Purdy, MD Halifax, Nova Scotia, Canada
Alan Rapoport, MD Los Angeles, California

Abstracts and Citations Editors
Wade Cooper, DO Ann Arbor, Michigan, USA
Robert Kaniecki, MD Pittsburgh, PA, USA
Frederick R. Taylor, MD Minneapolis, MN, USA

Book/Media Review Editor
R. Allan Purdy, MD Halifax, Nova Scotia, Canada

Expert Opinion Section Editor
Randolph W. Evans, MD Houston, TX, USA

Residents and Fellows Section Editors
Morris Levin, MD San Francisco, CA
Matthew S. Robbins, MD Bronx, NY

Statistical Consultant
Timothy Houle, PhD Boston, MA, USA

Design & Methods Advisor
Dana Turner Boston, MA, USA

Editorial Office
Jason Roberts, PhD
Executive Editor, Headache Ottawa, Ontario, Canada
Email: journal@ahsnet.org

AHS Executive Office
Linda McGillicuddy
American Headache Society CEO
Mount Royal, NJ USA
Copyright © 2018 by the American Headache Society

HEADACHE

The Journal of Head and Face Pain

http://mc.manuscriptcentral.com/headache

Official Publication of the American Headache Society

www.headachejournal.org

Volume 58, Number 8

September 2018

Page

Guest Editorials

The Importance of Statistical Power Calculations 1187
Dana P. Turner, MSPH, PhD; Timothy T. Houle, PhD

Have You Got the Power? Why Statistical Power Calculations Are Critical to Research Design 1192
Serena L. Orr, MD, MSc, FRCPC; Andrew D. Hershey, MD, PhD, FAHS

Research Submissions

Predictors of First-Line Treatment Success in Children and Adolescents Visiting an Infusion Center for Acute Migraine 1194

Serena L. Orr, MD, MSc, FRCPC; Marielle A. Kabbouche, MD; Paul S. Horn, PhD; Hope L. O'Brien, MD, FAHS, FAAN; Joanne Kacperski, MD; Susan LeCates, MSN, APRN, CNP; Shannon White, DNP, CNP; Jessica Weberding, MSN, CNP; Mimi N. Miller, MSN, APRN, CNP; Scott W. Powers, PhD, ABPP, FAHS; Andrew D. Hershey, MD, PhD, FAHS

Aura in Cluster Headache: A Cross-Sectional Study 1203
Ilse F. de Coo, MD; Leopoldine A. Wilbrink, MD; Gaby D. Ie, MD; Joost Haan, MD, PhD; Michel D. Ferrari, MD, PhD

Structured Clinical Documentation to Improve Quality and Support Practice-Based Research in Headache 1211
Steven Meyers, MD; Kelly Claire Simon, ScD; Stuart Bergman-Bock, MD; Franco Campanella, DO; Revital Marcus, MD; Angela Mark, MD; Thomas Freedom, MD; Susan Rubin, MD;

Irene Semenov, DO; Rebekah Lai, BS; Laura Hillman, BBA; Samuel Tideman, MS; Anna Pham, BS; Roberta Frigerio, MD; Demetrius M. Maraganore, MD

Migraine and Non-Migraine Headaches Following Diagnostic Catheter-Based Cerebral Angiography 1219
Adnan I. Qureshi, MD; Nishath Naseem, MD; Muhammad A. Saleem, MD; Anvita Potluri, MD; Faisal Raja, MD; Shawn S. Wallery, MD

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab 1225
David W. Ayer, PhD; Vladimir Skljarevski, MD; Janet H. Ford, PhD; Allen W. Nyhuis, MS; Richard B. Lipton, MD; Sheena K. Aurora, MD

Images From Headache

Central Skull Base Osteomyelitis Presenting Only With a Severe Headache 1236
Pahn K. Choi, MD; Ji Y. Chung, MD; Hyun G. Kang, MD, PhD

Brief Communications

Orthostatic Headache After Suboccipital Craniectomy Without CSF Leak: Two Case Reports 1238
Monique M. Montenegro, MD; Jeremy K. Cutsforth-Gregory, MD

Cerebral Venous Thrombosis in Spontaneous Intracranial Hypotension: A Report on 4 Cases and a Review of the Literature. 1244
Dan Zhang, MD; Jin Wang, MD; Qiaowei Zhang, MD; Feifang He, PhD; Xingyue Hu, MD, PhD



Scan this QR code with your smartphone to listen to the most recent Headache Journal podcast.



Qudexy[®] XR

(topiramate) extended-release capsules



Eliminating barriers with Qudexy[®] XR

With the Platinum Pass, it has never been easier to prescribe Qudexy[®] XR. Help patients start, stay and save on therapy today!



Get Your Patients Started on Qudexy[®] XR Today!
Visit hcp.QudexyXR.com or call Access Pathways[®] at 1-855-282-4887.

*Restrictions apply. Medicare, Medicaid, and other federal and state health care program patients are not eligible.

Qudexy and Access Pathways are registered trademarks of Upsher-Smith Laboratories, LLC.
© 2018 Upsher-Smith Laboratories, LLC, 6701 Evenstad Drive, Maple Grove, MN 55369 113236.02

UPSHER-SMITH

Partners in Health Since 1919

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.